Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5144 - Circulating Exosomal Integrin _v_5 Predicts Liver Metastasis and Prognosis in Human Colorectal Cancer

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Dake Chu

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

D. Chu

Author affiliations

  • Gastroenterology, First Affiliated Hospital of Xi'an Jiaotong University (School of Medicine), 710061 - Xi'an/CN
More

Resources

Abstract 5144

Background

Ever since the “seed-and-soil” hypothesis, the mechanism of cancer metastatic organotropism is still an unsolved mystery. In colorectal cancer (CRC), there is still no robust metastasis predictive biomarkers for distant organ metastasis, which is the most common cause of deaths. In spite of the function of exosome in RNA and protein delivery, its clinical significance in CRC metastasis remains uncertain. Here, we evaluated the potential role of serum exosome integrin in CRC metastasis.

Methods

Tissue integrin αvβ5 was quantified by quantitative reverse-transcription PCR in 31 pairs of primary CRC and corresponding matched liver metastasis (LM), with non-LM as control. Serum exosomal integrin αvβ5 was accessed by ELISA in 126 CRC patients with LM and 166 CRC patients without, as well as when LM was diagnosed in these 166 patients in exploratory cohort. In prospective validation cohort, serum exosomal integrin αvβ5 was investigated in 135 initially diagnosed CRC patients without metastasis. CRC-associated metastasis mouse models were established to verify the role of serum exosomal integrin αvβ5.

Results

Integrin αvβ5 level in LM was significantly increased compared with that in non-LM, which was correlated with its expression in primary CRC. Serum exosomal integrin αvβ5 was significantly increased in CRC patients with LM than those without, in a TNM stage-dependent manner. Moreover, it was found that serum exosomal integrin αvβ5 in CRC patients was significantly upregulated when LM occurred and associated with unfavorable survival. In validation cohort, increased serum exosomal integrin αvβ5 indicated higher risk of LM and unfavorable prognosis. Serum exosomal integrin αvβ5 was significantly increased in mice with LM compared with controls.

Conclusions

Our clinical and animal model data indicate that increased levels of serum integrin αvβ5 associate with CRC LM and unfavorable survival. These results suggested that circulating integrin αvβ5 could be a promising non-invasive predictor for CRC LM and prognosis.

Clinical trial identification

Legal entity responsible for the study

Xi'an Jiaotong University.

Funding

NSFC.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings